EW
Edwards Lifesciences Corp
NYSE · Healthcare · Medical - Devices · US
$88.26
+0.01%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$87.47
From 52W high−7.27%
Volume4.20M
Market cap$50.87B
P/E (TTM)50.7x
P/S (TTM)7.8x
Div yield—
Key dataSep 18, 2026
Open
$87.47
From 52W high
−7.27%
Volume
4.20M
Market cap
$50.87B
ValuationView details →
P/E (Fwd)
28.0x
EV/EBITDA
30.8x
P/E (TTM)
50.7x
RSI (14)
49.0
MomentumView details →
1D Return
+0.01%
YTD Return
+3.55%
SummaryUpdated Jun 1, 2026
Edwards Lifesciences Corporation (NYSE:EW) is a leading medical device company founded in 1958 and headquartered in Irvine, California. The company has evolved from its origins as a division of American Hospital Supply Corporation to become a specialized leader in structural heart disease and critical care monitoring technologies. Edwards went public in 2000 and has since focused increasingly on structural heart therapies, completing the sale of its Critical Care business in 2024 to concentrate solely on treating heart valve diseases and related conditions.
Similar companies
Latest newsMore news →
Daniel J. Lippis, CVP, TAVR at Edwards Lifesciences Corp, sold 619 shares of the company's common stock for $54,168 on September 11, 2026, and concurrently acquired 619 shares via employee stock option exercise at $72.68 per share.9d agoThe Centers for Medicare & Medicaid Services released a national coverage determination for transcatheter aortic valve replacement (TAVR), prompting a statement from Edwards Lifesciences.10d ago